Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Hartford HealthCare Black and Red Gala 2025
Sponsorship
Antitrust
Informa CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
IAM Live: Auto IP USA 2025
Speaking Engagement
Intellectual Property
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
A Labor of Love: Trump DOJ Obtains First Guilty Verdict in a Criminal Labor Case
Axinn Viewpoints
Antitrust
Managing Partner Jeny Maier Appears on Capitol Forum's ABA Spring 2025 Interview Series
Video
Antitrust